Shares of H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) traded down 49.5% during mid-day trading on Friday . The company traded as low as $2.02 and last traded at $2.02. 400 shares changed hands during mid-day trading, an increase of 288% from the average session volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Stock Down 49.5 %
The company’s fifty day simple moving average is $2.02 and its two-hundred day simple moving average is $2.02.
H-CYTE Company Profile
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
Featured Stories
- Five stocks we like better than H-CYTE
- Top Biotech Stocks: Exploring Innovation Opportunities
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 ETFs to Ride the VIX Surge During Market Volatility
- Investing in Commodities: What Are They? How to Invest in Them
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
